Patrzałek Marian, Albrecht Piotr, Sobczyński Maciej
NZOZ Promed w Kielcach.
Przegl Epidemiol. 2011;65(1):51-6.
In these article they made analysis of indirect, population effects of mass, free of charge, pneumococcal vaccinations (PCV7) on all-cause pneumonia incidence in Kielce, Poland. The strongest and significant fall (p=0.00079) in all-cause pneumonia incidence in the analyzed period 2005-2009 compared with remaining groups were observed in the group of children under 2 of years of life. He amounted to the 74% (around 25/1000 in 2005; 6/1000 in 2009). In the entire ancient group 0-29, embracing children under 2 yrs of life the fall of pneumonia incidence rate amounted to the 48% (from 2.8/1000 in 2005; 1.5/1000 in 2009). In the age 65+ group the fall in the incidence amounted to the 45% (19/1000 in 2005; <11/1000 in 2009 r.). At the moment they didn't observe, of such a fall in age groups 30-49 yrs and 50-64 yrs. Presented results are pointing population effectiveness of applied in Kielce mass vaccination in a 2+1 scheme. Analyzing only pneumonia requiring the hospitalization they tried at work to estimate, in the definitely simplified way, financial effects of mass pneumococcal vaccination in Kielce. Analysis showed at children up to 2 yrs frugalities of the row of the 174,420 zloty annually. In the group above 1 year of life analogous analysis showed frugalities of row 789,480 zloty. Results presented by us should, in our opinion, to induce decision-makers for free of charge mass pneumococcal vaccinations to entire Poland.
在这些文章中,他们分析了波兰凯尔采大规模免费肺炎球菌疫苗接种(PCV7)对全因肺炎发病率的间接人群效应。与其他组相比,在2005 - 2009年分析期内,2岁以下儿童组全因肺炎发病率出现了最强且显著的下降(p = 0.00079)。下降幅度达74%(2005年约为25/1000;2009年为6/1000)。在整个0 - 29岁年龄组(包括2岁以下儿童)中,肺炎发病率下降了48%(从2005年的2.8/1000降至2009年的1.5/1000)。在65岁及以上年龄组中,发病率下降了45%(2005年为19/1000;2009年降至<11/1000)。目前,在30 - 49岁和50 - 64岁年龄组未观察到这种下降情况。所呈现的结果表明了在凯尔采采用2 + 1方案进行大规模疫苗接种的人群有效性。仅分析需要住院治疗的肺炎病例时,他们试图以一种非常简化的方式估算凯尔采大规模肺炎球菌疫苗接种的财务影响。分析显示,2岁以下儿童每年节省174,420兹罗提。在1岁以上年龄组中,类似分析显示节省789,480兹罗提。我们认为,我们所呈现的结果应促使决策者在波兰全国范围内推行免费的大规模肺炎球菌疫苗接种。